 Jounce Therapeutics Inc. JNCE, -6.66 shares jumped more than 70 in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. GILD, 0.31 would completely acquire rights to an immunotherapy drug from Jounce. Gilead said it would buy out its remaining obligations under a licensing agreement executed in 2020 between the two companies and acquire intellectual property and rights to the cancer treatment, known as GS-1811. 